Frazier Life Sciences Management’s AnaptysBio ANAB Stock Holding History

Frazier Life Sciences Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,573,719	Closed	-$20.8M	–	48
2024 Q4	$20.8M	Sell	1,573,719 -635,470	-29%	-$15.4M	0.86%	25
2024 Q3	$74M	Buy	2,209,189 +43,598	+2%	+$1.49M	2.97%	13
2024 Q2	$54.3M	Buy	2,165,591 +1,265,891	+141%	+$29.5M	2.54%	12
2024 Q1	$20.3M	Hold	899,700	–	–	0.85%	31
2023 Q4	$19.3M	Hold	899,700	–	–	1.03%	27
2023 Q3	$16.2M	Hold	899,700	–	–	1.07%	22
2023 Q2	$18.3M	Hold	899,700	–	–	1.09%	22
2023 Q1	$19.6M	Hold	899,700	–	–	1.42%	19
2022 Q4	$27.9M	Hold	899,700	–	–	1.73%	14
2022 Q3	$23M	Hold	899,700	–	–	1.77%	16
2022 Q2	$18.3M	Hold	899,700	–	–	1.72%	16
2022 Q1	$22.3M	Buy	+899,700	New	+$27.2M	1.9%	17

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Frazier Life Sciences Management's ANAB Position: Q1 2025 in Review

Frazier Life Sciences Management sold out of AnaptysBio (ANAB) in Q1 2025, closing a stake of 1,573,719 shares — an estimated $20.8M sold.

Frazier Life Sciences Management first reported a position in ANAB in Q1 2022 and held it in 12 quarters. The position peaked at $74M in Q3 2024. 153 funds tracked by Wall St. Rank hold ANAB as of Q1 2025.

Frazier Life Sciences Management reported no remaining AnaptysBio position as of Q1 2025 after selling out during the quarter.
Frazier Life Sciences Management sold 1,573,719 AnaptysBio shares in Q1 2025, an estimated $20.8M.
Frazier Life Sciences Management first reported a position in AnaptysBio in Q1 2022 and held it in 12 quarters.
Frazier Life Sciences Management's AnaptysBio position peaked at $74M in Q3 2024.
153 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2025.

Based on Frazier Life Sciences Management's 13F filing for Q1 2025, filed 15 May 2025.